<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="869">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044249</url>
  </required_header>
  <id_info>
    <org_study_id>MP-101-01</org_study_id>
    <nct_id>NCT03044249</nct_id>
  </id_info>
  <brief_title>A Study of MP-101 in the Treatment of Psychosis in Alzheimer's Disease</brief_title>
  <official_title>Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Psychosis in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mediti Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mediti Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A ten-week study to assess MP-101 in the treatment of psychosis in participants with
      Alzheimer's Disease, as compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Neuropsychiatric Inventory (NPI) - Psychosis subscale</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in the Neuropsychiatric Inventory (NPI) psychosis subscale that covers delusions and hallucinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Global Impression of Severity (CGIS)</measure>
    <time_frame>Baseline up to ten weeks</time_frame>
    <description>Change from baseline in the Clinical Global Impression of Severity (CGIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Total Score</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Caregiver Distress</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI caregiver distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Domains</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI domains of anxiety and agitation/aggression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily living inventory (ADCS-ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in Cohen-Mansfield Agitation Inventory (CMAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any Treatment Emergent Adverse Event</measure>
    <time_frame>Baseline up to 11 weeks</time_frame>
    <description>Number of participants with untoward medical occurrences that emerge during the treatment period, having been absent pretreatment, or worsen relative to the pretreatment state, which do not necessarily have a causal relationship with this treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) part III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Plasma Levels of MP-101 and Metabolite</measure>
    <time_frame>Baseline up to 8 weeks</time_frame>
    <description>Parameters from weeks 2, 4, 6 and 8 combined utilizing a population approach</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psychosis</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>MP-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose administered orally once daily, starting at 20 milligrams up to 60 milligrams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-101</intervention_name>
    <description>Capsules</description>
    <arm_group_label>MP-101</arm_group_label>
    <other_name>LY2979165</other_name>
    <other_name>LY2812223</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females must be of non-childbearing potential, defined as women greater than or equal
             to (≥) 60 years of age, postmenopausal women ≥50 and less than(&lt;) 60 years of age who
             have had a cessation of menses for at least 12 months, or women who are congenitally
             or surgically sterile

          -  Males must agree to use 2 forms of highly effective birth control with female partners
             of childbearing potential while enrolled in the study, and for at least 28 days
             following the last dose

          -  Ambulatory (with or without walking device) with a stable gait

          -  Have a documented diagnosis of probable Alzheimer's Disease (AD)

          -  Able to communicate verbally

          -  Have psychotic symptoms that developed following the diagnosis of probable AD,
             including visual and/or auditory hallucinations, and/or delusions

          -  Have an NPI score of ≥4 on either individual item (delusions or hallucinations) or ≥6
             on the Psychosis Subscale (combined delusions and hallucinations)

          -  Have an Mini-Mental State Examination (MMSE) score of 10 to 24.

          -  Have had an Magnetic Resonance Imaging (MRI) or a computed tomography (CT) scan
             concurrent with or following the diagnosis of probable AD, to exclude prior stroke or
             structural brain disease

          -  Have a reliable caregiver/study informant who provides written informed consent to
             participate and who is in frequent contact with the patient (defined as spending at
             least 4 hours/day at least 4 days/week with the patient and who is knowledgeable about
             the patient's daytime and nighttime behaviors). The caregiver/study informant must be
             able to communicate with site personnel, and opinion of the investigator, must
             understand the written protocol-specified questionnaires. If a caregiver/study
             informant cannot continue, a replacement caregiver will be allowed if the above
             criterion is met

          -  Are receiving acetylcholinesterase inhibitors (AChEIs) on stable doses ≥3 months prior
             to or during the study, or in the opinion of the investigator will be likely to remain
             on a stable treatment regimen for 6 months. Patients not being treated with AChEIs are
             also eligible for study enrollment

          -  Have venous access sufficient to allow for blood sampling per the protocol

          -  Have clinical laboratory test results within normal reference range for the population
             or investigative site

          -  Are capable of participating in all study assessments

          -  Are able and willing to provide consent (patients and caregivers/study informants)

        Exclusion Criteria:

          -  Have a history of significant psychotic disorders prior to or simultaneous with the
             probable diagnosis of AD (including, but not limited to, schizophrenia and bipolar
             affective disorder)

          -  Meet National Institute of Neurological Disorders and Stroke/Association International
             pour la Recherche et l'Enseignement en Neurosciences criteria for vascular dementia

          -  Have an MRI or CT scan (on file since the onset of symptoms of AD) that is
             inconsistent with a probable diagnosis of AD

          -  Meet Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-V)
             criteria for delirium.

          -  Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) &lt;45
             milliliters per minute per 1.73 square meters (ml/min/1.73m2)

          -  Have psychosis from non-AD-associated etiologies (for example, substance abuse or a
             diagnosis of psychosis prior to the development of AD)

          -  Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or
             oncologic comorbidities that could impact patient safety and study participation over
             10 weeks

          -  Have a history of seizures or other condition that would place the patient at
             increased risk of seizures.

          -  Are, in the investigator's judgment, at risk for suicide, or as indicated by the
             Columbia Suicide Severity Rating Scale (C-SSRS)

          -  Have a Fridericia's corrected QT interval (QTcF) greater than (&gt;) 450 milliseconds
             (ms) for males or 470 ms for females

          -  Use any antipsychotics or any other drug intended to treat psychosis during the study.
             If the patient is taking the medication prior to study entry, there must be a washout
             period

          -  Are currently enrolled in any other clinical trial involving an investigational
             product or any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product. If the previous investigational product has a long half-life,
             at least 3 months (or more) must have passed

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mediti Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Mediti Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>317-651-7036</phone>
    <email>Mediti@Choruspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Maw</last_name>
      <phone>352-597-8839</phone>
      <email>kmaw@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Kelli Maw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Gamez</last_name>
      <phone>305-805-0921</phone>
      <email>jegamez@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Gamez</last_name>
      <phone>305-820-3381</phone>
      <email>jegamez@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research Inc</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigi Lefebvre</last_name>
      <phone>727-347-8839</phone>
      <email>glefebvre@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Gigi Lefebvre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research Corporation</name>
      <address>
        <city>Manchester Township</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Shua Haim</last_name>
      <phone>732-657-6100</phone>
      <email>shua-haim@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Joshua Shua Haim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono</last_name>
      <phone>718-317-5522</phone>
      <phone_ext>3</phone_ext>
      <email>dibuono@rbany.com</email>
    </contact>
    <investigator>
      <last_name>Mark DiBuono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>July 27, 2017</lastchanged_date>
  <firstreceived_date>January 31, 2017</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychotic Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

